Evidence map›Paper›PMID 28673276›Full record

ArticleBMC nephrology2017

Worldwide view of nephropathic cystinosis: results from a survey from 30 countries.

Aurélia Bertholet-Thomas, Julien Berthiller, Velibor Tasic, Behrouz Kassai, Hasan Otukesh, Marcella Greco, Jochen Ehrich, Rejane de Paula Bernardes, Georges Deschênes, Sally-Ann Hulton and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Adult complications of nephropathic cystinosis: a systematic review.Pediatric nephrology (Berlin, Germany) · 2021
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Paediatric nephrology in under-resourced areas.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 11 countries.

Aurélia Bertholet-ThomasCentre de référence des maladies rénales rares Néphrogones, hôpital Femme-Mère-Enfant, Hospices Civils de Lyon & Université Claude-Bernard Lyon 1, Lyon, France.
Julien BerthillerHospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Lyon, France.
Velibor TasicMedical School, University Children's Hospital, Skopje, Macedonia.
Behrouz KassaiHospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Lyon, France.
Hasan OtukeshAli Asghar children Hospital, Teheran, Iran.
Marcella GrecoDivision of Nephrology and Dialysis, Children's Hospital Bambino Gesù, IRCCS, Roma, Italy.
Jochen EhrichChildren's Hospital, Hannover Medical School, Hannover, Germany.
Rejane de Paula BernardesClinica Nefrokids, Curitiba, Brazil.
Georges DeschênesService de néphrologie pédiatrique, Hôpital Robert Debré, Université Sorbonne Paris, Paris, France.
Sally-Ann HultonBirmingham Children's Hospital, Birmingham, England.
Michel FischbachService de néphrologie pédiatrique, Hôpital Hautepierre, Strasbourg, France.
Kenza SoulamiPediatric Nephrology, 295 Bd Abdelmoumen, Casablanca, Morocco.
Bassam SaeedKidney Hospital, Damascus, Syria.
Ehsan ValaviDepartment of Nephrology, Jundishapur University of Medical Sciences, Ahvaz, Iran.
Carlos Jose CobenasHospital de Ninos Ludovica La plata, La plata, Argentina.
Bülent HacihamdiogluDepartment of Pediatrics of Gulhane Military, Gulhane, Turkey.
Gabrielle WeilerDivision of nephrology, Children's hospital of Eastern Ontario, Ottawa, Canada.
Pierre CochatCentre de référence des maladies rénales rares Néphrogones, hôpital Femme-Mère-Enfant, Hospices Civils de Lyon & Université Claude-Bernard Lyon 1, Lyon, France.
Justine BacchettaCentre de référence des maladies rénales rares Néphrogones, hôpital Femme-Mère-Enfant, Hospices Civils de Lyon & Université Claude-Bernard Lyon 1, Lyon, France. justine.bacchetta@chu-lyon.fr.
Hôpital Femme Mère Enfant · FRAhvaz Jundishapur University of Medical Sciences · IRBambino Gesù Children's Hospital · ITBirmingham Children's Hospital · GBCentre Hospitalier Universitaire Ibn Rochd · MAChildren's Clinical University Hospital · LVChildren's Hospital of Eastern Ontario · CADamascus Hospital · SYDélégation Régionale Auvergne-Rhône-Alpes · FRGülhane Askerî Tıp Akademisi · TRHôpital d'Hautepierre · FRHôpital Robert-Debré · FRHospices Civils de Lyon · FRHospital de Niños Superiora Sor María Ludovica · ARInserm · FRMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNephropathic cystinosis is a rare inherited metabolic disorder leading to progressive renal failure and extra-renal comorbidity. The prognosis relies on early adherence to cysteamine treatment and symptomatic therapies. Developing nations [DiN] experience many challenges for management of cystinosis. The aim of this study was to assess the management characteristics in DiN compared with developed nations [DeN].

methodsA questionnaire was sent between April 2010 and May 2011 to 87 members of the International Pediatric Nephrology Association, in 50 countries.

resultsA total of 213 patients were included from 41 centres in 30 nations (109 from 17 DiN and 104 from 13 DeN). 7% of DiN patients died at a median age of 5 years whereas no death was observed in DeN. DiN patients were older at the time of diagnosis. In DiN, leukocyte cystine measurement was only available in selected cases for diagnosis but never for continuous monitoring. More patients had reached end-stage renal disease in DiN (53.2 vs. 37.9%, p = 0.03), within a shorter time of evolution (8 vs. 10 yrs., p = 0.0008). The earlier the cysteamine treatment, the better the renal outcome, since the median renal survival increased up to 16.1 [12.5-/] yrs. in patients from DeN treated before the age of 2.5 years of age (p = 0.0001). However, the renal survival was not statistically different between DeN and DiN when patients initiated cysteamine after 2.5 years of age. The number of transplantations and the time from onset of ESRD to transplantation were not different in DeN and DiN. More patients were kept under maintenance dialysis in DiN (26% vs.19%, p = 0.02); 79% of patients from DiN vs. 45% in DeN underwent peritoneal dialysis.

conclusionsMajor discrepancies between DiN and DeN in the management of nephropathic cystinosis remain a current concern for many patients living in countries with limited financial resources.

Indexed as

Global HealthInternationalityPhysiciansSurveys and QuestionnairesAdolescentAdultChildChild, PreschoolCystinosisDeveloping CountriesFemaleFollow-Up StudiesHumansInfantKidney Failure, ChronicMaleCysteamineDeveloping nationsNephropathic cystinosis

Identifiers

PMID28673276
PMCPMC5496396
OpenAlexW2725647178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.